Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 6/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076896 | 0.89 | MAPT (0.44) | POLBMAPTTSHRPRMT5WDR77 | |
| SCHEMBL29426569 | 0.89 | MAPT (0.44) | POLBMAPTTSHRPRMT5WDR77 | |
| SCHEMBL24076279 | 0.84 | POLB (0.42) | POLBMAPTTSHRPRMT5WDR77 | |
| SCHEMBL26732910 | 0.83 | PARP1 (0.42) | POLBMAPTTSHRPRMT5WDR77 | |
| SCHEMBL29426515 | 0.83 | PARP1 (0.42) | POLBMAPTTSHRPRMT5WDR77 | |
| SCHEMBL24076885 | 0.82 | POLB (0.43) | POLBMAPTTSHRPRMT5WDR77 | |
| SCHEMBL24076877 | 0.78 | MAPT (0.39) | MAPTPRMT5WDR77SMN1; SMN2NPC1 | |
| SCHEMBL24076283 | 0.77 | HTT (0.44) | POLBTSHRPRMT5WDR77SMN1; SMN2 | |
| SCHEMBL24076276 | 0.76 | MAPT (0.36) | POLBMAPTPRMT5WDR77SMN1; SMN2 | |
| SCHEMBL30451535 | 0.75 | MAPT (0.45) | MAPTPRMT5WDR77SMN1; SMN2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | POLB 3231/4885MAPT 1004/4885TSHR 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.